CT45A3 (CT45.3): A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: CT45A3

NCBI ID: G441519

CT45A3

CT45A3 (CT45.3): A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

CT45A3 (CT45.3), also known as CD45, is a protein that is expressed in various tissues throughout the body, including the nervous system, gastrointestinal tract, and skin. It is a member of the CD45 family, which includes proteins that are involved in cell adhesion, migration, and signaling.

Recent studies have identified CT45A3 (CT45.3) as a potential drug target (or biomarker) for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because CT45A3 (CT45.3) is involved in the development and progression of these conditions, and may play a key role in the treatment of these diseases.

One of the reasons why CT45A3 (CT45.3) has been identified as a potential drug target is because it is involved in the development and progression of cancer. CT45A3 (CT45.3) has been shown to be involved in the regulation of cell growth, cell differentiation, and cell survival. It has been shown to play a role in the development of various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its role in cancer development, CT45A3 (CT45.3) has also been shown to be involved in the regulation of neurodegenerative diseases. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. CT45A3 (CT45.3) has been shown to be involved in the development and progression of these conditions, and may play a key role in the treatment of these diseases.

Another reason why CT45A3 (CT45.3) has been identified as a potential drug target is because it is involved in the regulation of autoimmune disorders. Autoimmune disorders are a group of conditions in which the immune system attacks the body's own tissues, leading to inflammation and damage. CT45A3 (CT45.3) has been shown to be involved in the regulation of the immune system, and may play a key role in the treatment of autoimmune disorders.

In conclusion, CT45A3 (CT45.3) is a protein that is involved in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target, CT45A3 (CT45.3) has the potential to be a valuable tool in the treatment of these diseases. Further research is needed to fully understand the role of CT45A3 (CT45.3) in these conditions, and to develop effective treatments.

Protein Name: Cancer/testis Antigen Family 45 Member A3

The "CT45A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT45A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets